Optimal duration of prior endocrine therapy predicts the efficacy of Fulvestrant in a real‐world study for patients with hormone receptor‐positive and HER2‐negative advanced breast cancer

Fulvestrant 500 mg is standard of care for endocrine therapy‐naive or pretreated women with hormone receptor‐positive (HR+) metastatic breast cancer (MBC). This study was conducted to explore the potential factors and duration of last endocrine therapy as predictors for the efficacy of fulvestrant 5...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Med
Main Authors: Zhao, Yannan, Li, Yi, Gong, Chengcheng, Xie, Yizhao, Zhang, Jian, Wang, Leiping, Cao, Jun, Tao, Zhonghua, Wang, Biyun, Hu, Xichun
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2020
Assuntos:
Clinical Cancer Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7724295/
https://ncbi.nlm.nih.gov/pubmed/33022852
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.3491
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados